Summary
Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome.

They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins - A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.

Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H) and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.

The total number of products under development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections is 54, 107, 58 and 31, respectively. Key companies operating in this pipeline space include Sanofi, Seqirus and NanoViricides.

This report “Influenza A Viral Infections Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for influenza A viral infections. It comprehensively documents therapeutics under development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.

Scope

Which companies are the most active within the pipeline for influenza A viral infections?

Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

What are the most important R&D milestones and data publications to have happened within this field?

Reasons To Buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration